Matthew Mittelbronn, MD
Dermatology · Fort Worth, TXNPI 1801838537
Payments from drug & device makers
Across 134 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$494
- AbbVie$447
- Novartis$379
- Regeneron Healthcare Solutions, Inc.$301
- Johnson & Johnson$222
- E.r. Squibb & Sons, L.L.C.$214
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,01897%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 19 | $494 |
| AbbVie | 17 | $447 |
| Novartis | 16 | $379 |
| Regeneron Healthcare Solutions, Inc. | 17 | $301 |
| Johnson & Johnson | 9 | $222 |
| E.r. Squibb & Sons, L.L.C. | 10 | $214 |
| Galderma Laboratories, L.p. | 7 | $182 |
| Incyte Corporation | 6 | $115 |
| UCB, Inc. | 4 | $107 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| LEO Pharma Inc. | 5 | $92 |
| Arcutis Biotherapeutics, Inc. | 4 | $90 |
| Biofrontera Inc. | 5 | $78 |
| Lilly USA, LLC | 4 | $78 |
| Almirall LLC | 3 | $62 |
| Convatec Inc. | 1 | $36 |
| Pfizer | 2 | $35 |
| Boehringer Ingelheim | 1 | $28 |
| Sun Pharmaceutical Industries Inc. | 1 | $27 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $17 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $14 |
How this compares
$3,118 in reported general payments places this provider in the 40th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 88 | $2,830 |
| Triamcinolone Acetonide | 101 | $1,107 |
| Ketoconazole | 50 | $656 |
| Metronidazole | 15 | $565 |
| Fluorouracil | 11 | $535 |
| Doxycycline Hyclate | 38 | $517 |
| Econazole Nitrate | 14 | $506 |
| Hydrocortisone | 37 | $493 |
| Clindamycin Phosphate | 18 | $401 |
| Mupirocin | 19 | $183 |
| Tramadol Hcl | 47 | $134 |
| Prednisone | 14 | $55 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Fort Worth
- Ronald PlottFort Worth$1.9M
- Patrick KeehanFort Worth$713K
- Stephen TyringWebster$14.1M
- Edward LainAustin$12M
- Mark LeeSan Antonio$10.9M
- John BrowningSan Antonio$10.7M
- Craig TellerBellaire$7.7M
- Patricia LeeWebster$7.2M
- Jennifer CatherDallas$4.9M
- Michael MigdenHouston$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.